Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer

After L858R and ex19del epidermal growth factor receptor (EGFR) mutations, ex20ins mutations are the third most common class of driver-mutations in non-small cell lung cancer (NSCLC). Unfortunately, first-, second-, and third-generation EGFR tyrosine kinase inhibitors (TKIs) are generally ineffectiv...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medicinal chemistry 2025-01
Hauptverfasser:	Milgram, Benjamin C, Borrelli, Deanna R, Brooijmans, Natasja, Henderson, Jack A, Hilbert, Brendan J, Huff, Michael R, Ito, Takahiro, Jackson, Erica L, Jonsson, Philip, Ladd, Brendon, O'Hearn, Erin L, Pagliarini, Raymond A, Roberts, Simon A, Ronseaux, Sébastien, Stuart, Darrin D, Wang, Weixue, Guzman-Perez, Angel
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!